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ABSTRACT 
Pulse pressure (PP) is a predictor and major risk factor for cardiovascular (CV) diseases as left ventricular hypertrophy, myocardial infarction, 
carotid hypertrophy, atherosclerosis, congestive heart failure and stroke as well as chronic renal failure progression. PP has been proved a strong 
forecaster of CV risk, particularly when it is higher than 60 mm Hg and more strongly relates to carotid hypertrophy and exte nt of atherosclerosis 
than systolic pressure. Isolated systolic hypertension (ISH) is common among the elderly and is accompanied by elevated pulse pressure. However, 
treatment of ISH may further raise the PP if diastolic pressure is lowered to a greater extent than systolic pressure. Several drugs for hypertension 
have the side effect of increasing resting PP irreversibly, other antihypertensive drugs, such as ACE inhibitors, have been shown to lower the PP. 
Various approaches made by researchers for the maintenance of normal PP to reduce the mortality caused due to CV events based on the abnormal 
PP. We briefly review the therapeutic consequences for the attenuation of elevated PP associated with various CV events.  
Keywords: Pulse pressure, Cardiovascular diseases, Arterial stiffness, Antihypertensive therapy. 
INTRODUCTION  
Pulse pressure is the pressure difference between systolic and 
diastolic pressures to create the pulse [1]. If resting blood pressure 
is (systolic/diastolic) 120/80mmHg, PP is 40 [2,3]. The systemic PP 
directly proportional to stroke volume (SV) i.e. the volume of blood 
ejected from the left ventricle during systole and inversely 
proportional to the compliance (C) of the aorta [4]. It can also be 
defined as the difference between the peak and the foot of the 
pressure wave, and it is indirect measure of pulsatile load on the left 
ventricle [5].  
The SV and C can be used to calculate the pulse pressure:   
PP = SV / C 
PP is determined by both cardiac and vascular factors. The cardiac 
ventricular ejection generates a primary pressure wave and heart 
rate has an independent influence on the shape of this wave [6]. 
Both longitudinal and cross-sectional components of the vascular 
system contribute to the shape of the arterial pressure wave and, 
thereby, to pulse pressure. The longitudinal constituent is the 
structural design of the arterial tree, which determines the major 
reflection sites for the pressure wave. The cross-sectional design of 
the vascular system consists of a geometric (diameter) and a 
structural (composition of vessel wall) component. Both diameter 
and composition of the vessel wall vary greatly when going from 
central to more peripheral arteries [7,8]. 
Low (narrow) pulse pressure  
A pulse pressure lesser than 40 indicates patient have poor heart 
function, while a higher PP may mean heart's valves are leaky (valve 
regurgitation). A number of factors are known to influence arterial 
wall behavior and therefore, PP [9]. It is considered abnormally low 
if it is less than 25% of the systolic value. In trauma a narrow PP 
suggests significant blood loss (insufficient preload leading to 
reduced cardiac output). If it is extremely low, i.e. 25 mmHg or less, 
the cause may be low SV, as in congestive heart failure and shock 
[10,11].  
Elevated pulse pressure 
Elevated PP can result from either elevated systolic blood pressure 
(SBP) or low diastolic blood pressure (DBP) or both [12]. The DBP 
peaks at and subsequently declines after age 55 years, while the SBP 
augments relentlessly with each decade of life [13,14]. Other causes 
of a widened PP, including severe anemia, aortic insufficiency, 
thyrotoxicosis     or     arteriovenous     shunting,     are     much   more  
 
uncommon [15]. An individual might have an elevated PP, but may 
or may not be hypertensive (e.g., BP = 190/130, PP = 60 mmHg, vs. 
BP = 125/65, PP = 60 mmHg). Similarly, an individual might have an 
elevated SBP, but may or may not have a widened PP (e.g., BP = 
150/90, PP = 60 mmHg, vs. BP = 150/110, PP = 40 mmHg) [1,16]. If 
the usual resting PP is consistently greater than 40 mmHg, e.g. 60 or 
80 mmHg, the most likely basis is stiffness of major arteries, 
atherosclerosis and vascular calcification, aortic regurgitation, 
arteriovenous malformation, hyperthyroidism or some combination 
[17,18].    
 
Pulse pressure is a function of SBP and DBP and is dependent on SV 
and arterial wall elastic properties [19,20]. In a young healthy 
person, each SV received into the central vessels is accommodated 
by a stretching of these vessels in systole followed by subsequent 
elastic recoil in late systole and diastole. This is known as arterial C 
and has the effect of maintaining central and peripheral BP within a 
relatively narrow range. With aging, there is a disruption and 
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fragmentation of the elastic lamellae of the central arteries, as well 
as alteration of the collagen-to-elastin ratio [21], leading to arterial 
stiffness, loss of C, and increased PWV and therefore increased PP 
[22,23]. In hypertension to older age, arterial stiffness increases, 
diastolic decreases, central systolic and pulse pressures are 
augmented due to increase in pulse wave and early revisit of waves 
from the periphery to the heart [24]. Bidirectionality property of 
elevated PP mentioned in figure 1.  
Clinical events related to elevated PP 
Epidemiological studies in the past decade have stressed the 
importance of PP as an independent prognostic marker for 
cardiovascular morbidity and mortality [7,25-29]. Panagiotakos and 
colleagues, in a seven-country prospective study of 12,763 people 
living in the United States, Japan, Italy, Greece, Finland, former 
Yugoslavia and The Netherlands, identified PP, followed by DBP and 
SBP, as the best predictor for CVD mortality over the twenty-five-
year follow up period [1,30].  
Hypertension with elevated PP causes more arterial damage 
compared to high BP with normal PP [17]. Hypertensive patients of 
older age with higher PP and associated with diabetes, generally 
prefers calcium channel blockers and diuretics for treatment. The 
higher PP is sometime associated with elevated LV mass [31] and 
cause LVH, prolonged isovolumic relaxation time and higher stroke 
index. Elevated PP may associate with both increased SV and arterial 
stiffness [13,32]. A number of studies in humans and rats suggest 
consistent associations between body weight and arterial stiffness, 
independent of age, MAP and HR [33].  
Various factors such as reduction of elastic fibres in arteries [21], an 
increased expression of substances (endothelin, thromboxan, etc.) 
for their vasoconstriction properties and decrease in substances 
(bradykinin, nitric oxide) that produces vasodilation are responsible 
to elevate the pulse pressure [26]. 
Cardiovascular diseases associated with elevated pulse 
pressure 
With aging, the cardiac load tends to increase, because of a 
disproportional augmentation of central than brachial arterial 
stiffness that raises central PP and thus reduces peripheral PP 
augmentation [15,34]. This process favors the development of 
cardiac hypertrophy and/or CHF [35-38]. High PP is predictor of 
cardiovascular death after myocardial infarction as well as chronic 
renal failure progression [39-42].  If the PP is low usually, it reflects 
a low SV and this means that heart is not pumping out the right 
amount of blood that it is supposed to. This could be due to a very 
serious problem like CHD or shock [10]. A low PP ≤20 mmHg, in a 
blood pressure of 90/70 mmHg for example, may represent a 
decrease in cardiac output [43] and reflects a reduction of SV due to 
left ventricular dysfunction [10,14].  
Arterial stiffness, the hallmark of vascular aging, magnifies the 
augment in BP during systole and its decline during diastole [44]. 
Pulse pressure is an established index of arterial stiffness. It reflects 
the age-related deterioration of the elastic properties of the large 
arteries. Decreased arterial elasticity independently predicts the risk 
of cardiovascular events [29,45-47]. Arterial stiffness is a general 
term that collectively describes distensiblity, C, and elastic modulus 
of the arterial vascular system. It can be measured by using a simple 
technique i.e. pulse wave analysis (PWA) [48] which is noninvasive 
technique and used in epidemiological [49] and interventional 
studies [50]. It gives information about mechanical properties of the 
arterial structure [51] and can also be used to evaluate function of 
endothelial cells [52].  
Increase in arterial stiffness and premature vascular aging are 
coupled with decreased glomerular filtration rate and is indicator of 
chronic renal disease progression and end-stage renal disease 
(ESRD) [53]. In a study, it was found that increased arterial stiffness 
is associated with smaller PP amplification with increasing adiposity 
and hence obesity/overweight is associated with higher systolic 
pressure and PP [54]. Untreated hypertension accelerates the rate of 
development of large artery stiffness and perpetuates a vicious cycle 
of accelerated hypertension, further increasing the arterial stiffness 
and hence PP. Appropriate control of BP could reduce the 
hypertension-induced progression of arterial stiffness [55]. Elevated 
PP is associated with an increased risk of CV death in patients on 
peritoneal dialysis (PD). Recognition of this characteristic as an 
important predictor of mortality suggests that one goal of 
antihypertensive therapy in PD patients should be to decrease 
elevated pulse pressure [56]. Elevated pulse pressure are 
responsible for the stretching of arteries, provoke weariness and 
rupture of elastic elements, and rupture of aneurysms that leads to 
atherosclerosis and thrombotic events [34]. 
Elevated PP is also associated with cognitive decline and increased 
risk of Alzheimer's disease (AD) in older adults. Sixty-five elderly 
patients (mean age 74.2 years) clinically diagnosed with possible or 
probable AD underwent neuropsychological testing and BP 
examinations. Results demonstrated that antemortem PP elevation 
was associated cerebrovascular disease at autopsy suggests that in 
older adults with AD, PP elevation may increase the risk of 
cerebrovascular disease. These findings may have treatment 
implications since some antihypertensive medications specifically 
address the pulsatile component of BP (e.g., renin-angiotensin 
system (RAS) inhibitors and CCB) [57]. 
SBP and PP appear to be the major determinants of the tone of the 
afferent arterioles, independent of MAP and DBP [58,59]. In fact, 
recent clinical studies indicate that hypertensive renal injury 
correlates most strongly with SBP and PP [60,61]. Excess PP has also 
been recognized to cause vascular injury in the systemic circulation 
predicting adverse cardiovascular outcomes, unaffected by current 
antihypertensive therapy [62]. A PP combined with bradycardia is 
associated with increased intracranial pressure. A high resting PP is 
unsafe and tends to speed up the normal aging of body organs, 
particularly the heart, the brain and kidney.  
Approaches for Treatment 
A number of studies have been carried out to compare the effects of 
different agents and classes on arterial properties that are relevant 
to the issue of PP. Several studies have identified that high PP is 
affected differently by different hypertensive agents [17], despite 
similar effects on peripheral (brachial) BP [63]. Lifestyle and dietary 
modifications like smoking cessation [64], use of unsaturated fatty 
acids [65], isoflavones [66], less intake of dietary salt [67], regular 
exercise [68], and limited alcohol consumption [69,70] may helps to 
maintain the normal vascular stiffness. Pharmacologic interventions 
like use of antihypertensives as CCBs, diuretics, ACEIs, β-blockers, 
nitrates, phosphodiesterase-5-inhibitors, and statins to reduce the 
pulse pressure and hence arterial stiffness. Even though all these 
therapies lower blood pressure, their effect on arterial stiffness is 
only modest [15]. Optimal antihypertensive drug should decrease 
SBP and arterial stiffness without an increase of pulse pressure.  
Angiotensin converting enzyme inhibitor (ACEI): 
In a placebo controlled crossover study of acute effects of the ACEI, 
quinapril, in patients with essential hypertension, there were 
increase in carotid artery distensibility and aortic C (determined by 
PWV). The effects on aortic distensibility appeared to be a 
combination of direct and BP dependent effect [71]. Pulse pressure 
was reduced by similar amount at both carotid and brachial sites. In 
another study, intravenous dihydralazine or perindoprilat, did not 
alter significantly to the carotid-femoral PWV in patients with 
hypertension [72].  
Twenty-seven hypertensive patients were randomised to receive 
lisinopril (20 mg) or losartan (50 mg) for 5 weeks, and were 
subsequently crossed-over to the alternative treatment for a second 
5-week period. Lisinopril was found more effective than losartan in 
reducing elevated pulse pressure [73]. Antihypertensive agents 
acting as vasodilators, such as ACEIs and ARBs, have been shown to 
improve arterial C [73,74,75]. In an animal study, pulse pressure was 
reduced in the captopril-treated spontaneously hypertensive rats 
(SHR) [76]. 
In a study on 24 normotensive elderly subjects, administration of an 
ACEI ameliorated age-related increase in carotid arterial stiffness 
[77]. In the regression of arterial stiffness in a Controlled Double 
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Blind Study trial, the ACEI perindopril decreased aortic systolic and 
pulse pressure superior than the β-blocker atenolol [78]. In another 
study, all class of antihypertensive drugs decreased MAP in 
spontaneous hypertensive rats, only the CCB, nicardipine and ACEI, 
perindoprilat reduced proximal pulse pressure. This dissociation 
between the effects on MAP and proximal and distal PP can be 
explained by the preferential action of the different antihypertensive 
agents on large arteries and wave reflections, producing different 
patterns in the pulsatile component of the heart load [79]. In older 
men, ACEIs alone or in combination with diuretics may be more 
effective in lowering mean PP [80]. 
In an open randomized cross-over trial on sixty seven chronic 
kidney diseased (CKD) patients, combined RAS blockade with 
enalapril and candesartan caused additive significant BP 
independent reduction in aortic PWV and arterial stiffness 
compared to monotherapy [81]. However in another study, 
omapatrilat, a combination ACEIs and vasopeptidase inhibitor 
reduced arterial stiffness and consequently PP better than the ACEI, 
enalapril [40]. Ramipril produced BP independent reduction in 
aortic PWV in hypertensive subjects treated for 6 weeks [82]. 
In a retrospective analysis of the hypertensive subjects of the 
multicenter double-blind study, in which fixed first-line 
antihypertensive combination therapy with an ACEI, perindopril (2 
mg), and a diuretic, indapamide (0.625 mg), found more effective 
than atenolol in normalizing PP [83]. Antihypertensive therapy with 
angiotensin II receptor blockers (losartan) or ACEI (trandolapril) 
has been shown to have a beneficial effect on atherosclerosis or 
arterial stiffness in patients with ESRD [84,85]. 
In this study, 101 patients with mild essential hypertension were 
randomly assigned to an 8-week period of monotherapy with 
enalapril 10 mg a day or indapamide 2.5 mg a day. Central as well as 
brachial systolic, augmented, and pulse pressure were determined. 
Results infer a reduction in wave reflection with enalapril, causing a 
fall in aortic pressure augmentation, and a corresponding reduction 
in aortic systolic and pulse pressure. Results showed that a diuretic, 
a β-blocker agent, is not as effective a therapy as an ACE inhibitor in 
reducing pulse pressure [86].  
Angiotensin receptor blockers 
In a seven randomized, double blind, placebo controlled studies, 6 to 
12 week efficacy trials of olmesartan 20 mg and 40 mg/day were 
analyzed to determine changes in SBP and PP. Olmesartan 
significantly reduced SBP and PP, and these reductions were more 
pronounced in patients with a wide baseline PP [87]. In a 4 week 
single blind randomized crossover study, effect of losartan (50 
mg/day) to hydrochlorthiazide (12.5 mg/day) on BP and arterial 
stiffness was compared in 11 untreated hypertensive patients aged 
47 to 69 years. Both drugs produced decrease in brachial BP but 
only losartan induced a decrease in arterial wave reflection with a 
preferential reduction in aortic compared to brachial PP. Losartan 
also increased PP amplification and reduced PWV. These results 
suggest that an AT1 receptor antagonist induces a BP independent 
decrease in aortic stiffness and arterial wave reflection [88].  
Alpha- adrenergic blockers 
In an acute invasive study in which aortic PWV was inferred from 
the first minimum of the impedence modulus, PWV was unaffected 
by beta adrenoceptor blockade but was reduced by combined alpha 
and beta blockade [89]. Alpha-adrenoceptor blocker not showed 
direct effect in the augmentation of PP in any study.  
β-adrenergic blockers 
When the antihypertensive effects of β-blockers were compared 
with those of thiazide diuretics, the researchers identified the 
difference in effect on DBP, indicating that β-blockers have little or 
no effect on PP, whereas, thiazides cause a significant dose-related 
decrease in PP [90,91]. In a study, the effect of carvedilol and its 
combination with captopril on PP, LVH, kidney vascular changes and 
kidney function in SHR with adriamycin nephropathy. Indicated that, 
carvedilol alone, but more sturdily in combination with captopril, 
reduced blood pressure, PP, LVH, renal blood vessel changes and 
chronic renal failure progression.[39] In another study, nebivolol and 
nitrates produced a significant lowering of pulse pressure and an 
increase of the arterial C suggesting a beneficial effect that could 
promote the regression of left ventricular hypertrophy [92]. 
In a retrospective study, compared three groups of hypertensive 
patients (aged 35-65 years) chronically treated with either ARBs, 
carvedilol/nebivolol or atenolol, matched for age (mean 52 years), 
sex (61% female), brachial BP and concomitant use of diuretics (75-
81%) and dihydropyridine calcium antagonists (27-33%). Result 
indicated that, for similar brachial BP and aortic stiffness, treatment 
with either vasodilating β-blockers or ARBs associated with lower 
central systolic BP and wave reflections than treatment with 
atenolol, suggesting that the vasodilating β-blockers might exert 
more favourable central haemodynamic effects, compared with 
atenolol, which were more alike, although not completely equal, to 
those of the ARBs [93]. 
In a clinical trial, atenolol and losartan reduced brachial systolic and 
pulse pressure in the same amount. However, atenolol reduced 
aortic systolic and pulse pressure 28 and 11 mm Hg, respectively, 
whereas losartan reduced aortic systolic and pulse pressure 40 and 
23 mm Hg, respectively. Atenolol had little effect on radial and aortic 
augmentation indices, whereas losartan had a marked lowering 
effect [94,95]. 
Calcium channel blockers (CCBs) 
In the Anglo-Scandiavian Cardiac Outcomes Trial (ASCOT), CCB 
reduced risk of stroke about 27 %. In the same study, statin therapy 
did not lead to a reduction of central BP or augmentation index [96]. 
In a double blind, crossover comparison of 12 weeks treatments 
with the felodipine (a CCB) or the diuretic hydrochlorthiazide in 
subjects with mild to moderate hypertension, there were more 
pronounced fall in PWV at carotid-femoral as well as peripheral sites 
with felodipine. The finding of brachial artery dilation with 
felodipine, but not hydrochlorthiazide, however, indicated direct 
arterial wall effects of the CCB [97]. In a study of 8 months treatment 
to hypertensive subjects, nicardipine improved the peripheral C, 
determined by brachial radial PWV measurement but not by the 
atenolol [98]. The lowest central aortic pressures were achieved 
with calcium-blocking drugs and diuretics [99].   
In a study spontaneous hypertensive rats chronically treated with 
verapamil, MAP was unchanged and PP was reduced, whereas 
carotid internal diameter, medial thickness and collagen content 
were reduced to some extent in normotensive rats [100]. The dose 
of verapamil principally lowered basal pulsatile vascular load and 
ventricular systolic contractile function, reflecting reductions of 
systolic ventricular and vascular stiffening [101].  
Diuretics and vasodilators 
In a cross-sectional study on 1429 subjects aged 60 years or older 
who reported receiving one or two hypertensive drugs from the 
following medication classes: β-blockers, diuretics, CCBs, or ACE 
inhibitors. Older hypertensive subjects who used diuretics alone or 
in combination with β-blockers had lower mean pulse pressure as 
compared with those using other agents or β-blockers alone. These 
findings lend support to recommendations for use of diuretics in 
older hypertensive patients [17,102].  One more study on 
hydrochlorothiazide and clonidine, produced reductions in PP, but 
clonidine was associated with a much higher incidence of side effects 
and drug withdrawals, and central α-agonists have not been shown 
to reduce cardiovascular events as initial therapy in clinical trials 
[103]. In a comparative study of five antihypertensive agents of 
some classes: two ACEI i.e. perindopril and captopril, isradipine 
(CCB), hydralazine (a vasodilator) and metoprolol (β-blocker) 
indicated that a reduction in PP and HR during antihypertensive 
treatment might be important in preventing the development of 
abnormal small artery structure in hypertension [32]. 
In a 10-year study on 640 hypertensive subjects at the outpatient 
department of the Abidjan Heart Institute, the keypoint was to find 
out the prevalence of a high PP, the correlation between PP and CV 
risk factors, the impact of PP on target organs, and the variation in 
PP while on treatment during follow up. Dual therapy with a diuretic 
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was reported to have greater effect in controlling the pulse pressure 
compared to patients without a dual diuretic [104].  
Nitrates 
Nitrates (e.g. isosorbide mononitrate, nitroglycerin) decrease PP 
higher than MAP and are prescribed for the treatment of isolated 
systolic hypertension (ISH). Nitrates produce drug tolerance during 
chronic treatment so an asymmetric dosing regimen may prevent 
loss of effect of nitrates [25,105,106]. Nitrates not influence aortic 
stiffness even though they reduced PP by selective endothelium-
independent vasorelaxation and attenuation of peripheral wave 
reflection [15,107,108]. Nitroglycerin lowers mean BP in both age 
groups but reduces PP only in the old age group [109]. In a 
longitudinal cohort design study, PP, pulse wave and augmentation 
pressure were estimated in 411 female twins over a mean follow-up 
of 10.8 years. In a subsample (n=42), PP, arterial stiffness and 
arterial diameters were measured before and after nitroglycerin 
administration (400 µg s/l). It was observed that age-related 
widening of central PP is driven in large part by an increase in AP, 
which can be reversed by selective dilation of muscular arteries, 
independent of PWV [25].  
Other 
A study reported that 5 mg of folate daily over a three-week period 
reduced PP by 4.7 mmHg compared with a placebo and concluded 
that folic acid is an effective supplement that targets large artery 
stiffness and may prevent ISH [110]. Phosphodiesterase-5 inhibitors 
like sildenafil work similarly to nitrates and also reduce wave 
reflection and lower PP, but without the side effects of nitrates 
[111].   
Conclusion 
Pulse pressure is a biomarker of a number of cardiovascular 
diseases and the risks increases when it is higher than 60 mmHg. 
Pulse pressure is directly proportional to the arterial stiffness and 
incessantly increases with aging and hence increasing the risk of 
cardiovascular events. Various approaches have been made by the 
researchers for the attenuation of elevated pulse pressure to reduce 
mortality causes due to CVD associated with it. Antihypertensive 
drugs such as ACE inhibitors and ARBs reduced the elevated pulse 
pressure greater than the other class of antihypertensives. A diuretic 
in combination with β-blocker reduces PP effectively as compared to 
monotherapy. α-blockers are not effective in the augmentation of PP, 
whereas, verapamil (CCB) reduces systolic pressure and vascular 
stiffening. Nitrates decreases PP more than MAP but develops 
tolerance during chronic treatment. Monotherapy with hypertensive 
drugs is not sufficient to reduce widened pulse pressure effectively, 
hence, there is need of combination or supplementation with 
another drug or supplement diet (containing folic acid or Vitamin E) 
that helps to reduce the arterial stiffness. However, there is 
necessitate of more research in the field of therapies that specifically 
target PP, rather than mean pressure to control the CVD caused due 
to widened pulse pressure.   
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